TerminatedPHASE1, PHASE2NCT01752569

A Study of Selumetinib in Patients With Kaposi's Sarcoma

Studying Acquired immunodeficiency

Last synced from ClinicalTrials.gov

ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing data

Key facts

Sponsor
Sheffield Teaching Hospitals NHS Foundation Trust
Principal Investigator
Mark Bower, Professor
Chelsea & Westminster Hospital, London
Intervention
Selumetinib(drug)
Enrollment
19 enrolled
Eligibility
18 years · All sexes
Timeline
2012 – 2017

Study locations (6)

Collaborators

University of Birmingham · AstraZeneca · Thermo Fisher Scientific, Inc · Cancer Research UK · University of Sheffield

Primary source

Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.

Open NCT01752569 on ClinicalTrials.gov

Other trials for Acquired immunodeficiency

Additional recruiting or active studies for the same condition.

See all trials for Acquired immunodeficiency →

← Back to all trials